New obesity pill shows promise in early Fat-Burning study
NCT ID NCT06824051
First seen Jan 22, 2026 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-stage study tested an oral drug called orforglipron in 120 adults with obesity or overweight (but without diabetes). The goal was to see how it changes body fat compared to a placebo over about 8 months. Researchers measured fat around organs, appetite, and weight. This is a first step to see if the drug might become a future weight-loss treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Axis
Dilworth, Minnesota, 56529, United States
-
Clinical Pharmacology of Miami
Miami, Florida, 33172, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
Ohio Clinical Trials
Columbus, Ohio, 43212, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
orforglipron (an oral drug)
What this could lead to
If it works, this could point toward a new daily pill to help people with obesity or overweight lose body fat.
What could go wrong
This is a very early Phase 1 study with only 120 people, so results may not hold up in larger trials. The drug may cause side effects or fail to reduce fat significantly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.